Latest news with #AnnualGeneralMeetingof
Cision Canada
09-07-2025
- Business
- Cision Canada
Aritzia Reports on Voting Results from the 2025 Annual General Meeting of Shareholders and Changes to Board of Directors
VANCOUVER, BC, July 9, 2025 /CNW/ - The Annual General Meeting of Shareholders (the "Meeting") of Aritzia Inc. (TSX: ATZ) ("Aritzia" or the "Company"), a vertically integrated, innovative design house offering Everyday Luxury online and in its boutiques, was held yesterday via live webcast online. Each of the matters voted upon at the Meeting is discussed in detail in the Company's Management Information Circular dated May 26, 2025 (the "Circular"), which can be found under the Company's profile on SEDAR+ ( The total number of votes cast by shareholders in person and by proxy at the Meeting was 265,198,248 votes. The voting results in relation to the election of directors were as follows: Number of Votes Cast Name of Director Votes For Votes Withheld John Currie 259,193,065 4,325,953 Nicholas ("Nick") Drake 263,409,785 109,233 Brian Hill 256,660,844 6,858,174 David Labistour 262,630,013 889,005 Frank Douglas ("Doug") Mack 263,409,165 109,853 Marni Payne 261,656,150 1,862,868 Glen Senk 260,500,387 3,018,631 Marcia Smith 258,646,384 4,872,634 Jennifer Wong 263,277,945 241,073 The proposal with respect to the reappointment of PricewaterhouseCoopers LLP as the Company's auditor, as further described in the Circular, was approved. The Company has filed a report of voting results on all resolutions voted on at the Meeting under its profile on SEDAR+ ( As previously disclosed, Doug Mack was appointed to the Board effective May 26, 2025 to fill the vacancy caused by John Montalbano's resignation as a director on February 17, 2025 in order to pursue new endeavors and Nick Drake was a new director nominee at the Meeting. Aldo Bensadoun and Daniel Habashi did not seek re-election at the Meeting. Chairman of the Board, Brian Hill stated, "I am grateful to Aldo, Daniel and John for their significant contributions and long-standing support. Their unique perspectives have been instrumental in guiding and supporting our strategy." "The additions of Nick and Doug complement the strengths and experiences of our current Board of Directors, enriching our ability to execute our growth strategies as we bring Everyday Luxury TM to more and more clients around the world," added Mr. Hill. "Nick and Doug are esteemed leaders with a strong grasp of today's dynamic retail landscape," said CEO Jennifer Wong. "We look forward to their valuable contributions and support in delivering long-term value for our stakeholders." Mr. Mack served as the Chief Executive Officer of Fanatics, Inc. from 2014 to 2021 and as Vice Chairman of Fanatics and Chief Executive Officer of Fanatics Commerce through the end of 2023. Previously, Mr. Mack was the Chief Executive Officer of One Kings Lane and Chief Executive Officer and co-founder of Scene7. He currently serves on the Board of Recreational Equipment, Inc. and has previously served on the boards of Kate Spade & Company and Gerson Lehrman Group. Mr. Drake has served as the Vice President of Global Marketing at Google LLC since 2019. Prior to joining Google, Mr. Drake held senior advertising and marketing roles at companies including adidas America Inc., TBWA\Chiat\Day, Quiksilver, Inc. and T-Mobile USA Inc., where he most recently served as an Executive Vice President from 2017 to 2019. Mr. Drake currently serves on the Board of SGVC. About Aritzia Aritzia is a design house with an innovative global platform. We are creators and purveyors of Everyday Luxury TM, home to an extensive portfolio of exclusive brands for every function and individual aesthetic. We're about good design, quality materials and timeless style — all with the wellbeing of our People and Planet in mind. Founded in 1984 in Vancouver, Canada, we pride ourselves on creating immersive, highly personalized shopping experiences at and in our 130+ boutiques throughout North America — for everyone, everywhere. Our Approach Aritzia means style, not trend, and quality over everything. We treat each in-house label as its own atelier, united by premium fabrics, meticulous construction and an of-the-moment point of view. We handpick fabrics from the world's best mills for their feel, function and ability to last. We obsess over proportion, fit and that just-right silhouette. From hand-painted prints to the art of pocket placement, our innovative design studio considers and reconsiders each detail to create essentials you'll reach for again, and again, and again.
Business Wire
26-06-2025
- Business
- Business Wire
QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman following the Annual General Meeting of Shareholders (AGM) on June 26, 2025. He succeeds Lawrence A. Rosen, who did not stand for re-election after serving for 12 years on the Supervisory Board. The Dutch Corporate Governance Code indicates that Directors of public companies should not serve more than 12 years for a company on their Supervisory Board. At the AGM, where 80.4% of QIAGEN's issued shares were represented, shareholders approved all proposed resolutions, including the initiation of an annual cash dividend and a new share repurchase authorization of up to $500 million. Mr. Rusckowski joined the Supervisory Board in 2023 and has served as Chairman of the Nomination & Governance Committee and as a member of the Human Resources & Compensation Committee. He brings deep global healthcare and leadership experience, having previously served as Chairman, President and CEO of Quest Diagnostics and as CEO of Philips Healthcare. Mr. Rusckowski said: 'QIAGEN has built an outstanding portfolio of solutions trusted for their quality and scientific excellence. What continues to impress me is the clear vision that drives this company: a commitment to making improvements in life possible. I take on this role with deep respect for QIAGEN, its culture and its people, and with a clear recognition of the Supervisory Board's responsibility to be a strong and engaged partner for shareholders and other stakeholders.' Mr. Rosen stepped down after serving as Chairman since 2020 and serving as a member of the Supervisory Board since 2013. Under his leadership, QIAGEN underwent a period of focused strategic transformation and strengthened governance. Five new members have joined the Supervisory Board since 2020, enhancing its already strong international profile and deep expertise. 'It has been an extraordinary privilege to serve QIAGEN through a period of meaningful transformation and growth, and I believe QIAGEN has never been in a stronger position,' Mr. Rosen said. 'I will very much enjoy watching the progress as the employees of QIAGEN do great things to help our customers advance science and improve healthcare for people around the world.' Additionally, Prof. Dr. Elaine Mardis stepped down from the Supervisory Board after deciding not to stand for re-election. Prof. Dr. Mardis brought important scientific expertise to the Board since 2014, especially through her service on the Science & Technology and Human Resources & Compensation Committees. Following the AGM, QIAGEN's Supervisory Board now consists of eight members, reflecting the implementation of a plan announced in 2024 to return to a size consistent with historical levels and continuing to represent all the necessary expertise to support the future development of QIAGEN in a highly effective manner. The AGM approved the re-appointment for one-year terms of the following Board members: Dr. Metin Colpan, Dr. Toralf Haag, Prof. Dr. Ross L. Levine, Mr. Bert van Meurs, Ms. Eva van Pelt, Dr. Eva Pisa, Ms. Elizabeth Tallett and Mr. Stephen H. Rusckowski. Shareholders also approved the initiation of QIAGEN's first-ever annual cash dividend - a milestone that reflects QIAGEN's strong financial position and disciplined capital allocation strategy, which includes dividends in addition to organic investments, value-creating acquisitions and share repurchases. The first dividend payment will be $0.25 per ordinary share, totaling approximately $54 million, with a record and ex-date of July 2, 2025, and payment date of July 10, 2025. In addition, the AGM approved a new synthetic share repurchase authorization of up to $500 million, reinforcing QIAGEN's commitment to returning capital to shareholders while preserving financial flexibility to invest in innovation and long-term growth. About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed more than 5,600 people in over 35 locations worldwide. For more information, visit Forward-Looking Statement Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the 'Risk Factors' contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission. Source: QIAGEN N.V.
Hamilton Spectator
24-06-2025
- Business
- Hamilton Spectator
Probe Gold Announces Results of Annual General Meeting
TORONTO, June 24, 2025 (GLOBE NEWSWIRE) — Probe Gold Inc. (TSX: PRB) (OTCQB: PROBF) ('Probe' or the 'Company') announces the voting results for the Annual General Meeting of Shareholders (the 'Meeting') held today, in Toronto. Results of the Meeting The Company is reporting the voting results of its Meeting held on Tuesday, June 24, 2025. The summary of the results as follows: Election of Directors Based on the proxies received and the votes cast at the Meeting, each nominee director was elected to serve until the next annual meeting of shareholders. The following is a tabulation of the votes submitted: Appointment of Auditors Based on the proxies received and the votes cast at the Meeting, MNP LLP was appointed as the Company's auditor. The following is a tabulation of the votes submitted: Approval of Unallocated Entitlements Based on the proxies received and the votes cast at the Meeting, Unallocated Entitlements were approved. The following is a tabulation of the votes submitted: Please refer to the Company's Report of Voting Results filed on SEDAR at for further details on the above matters. About Probe Gold: Probe Gold Inc. is a leading Canadian company focused on the acquisition, exploration, and development of highly prospective gold properties. The Company is well-funded and dedicated to exploring and developing high-quality gold projects. Notably, it owns 100% of its flagship asset, the multimillion-ounce Novador Gold Project in Quebec, as well as an early-stage Detour Gold Quebec project. Probe controls a large land package of approximately 1835-square-kilometres of exploration ground within some of the most prolific gold belts in Quebec. The Company's recent Novador updated Preliminary Economic Assessment outlines a robust mining plan with an average annual gold production of 255,000 ounces over a 12.6-year mine life. Val-d'Or properties include gold resources totaling 6,728,600 ounces in the Measured and Indicated category and 3,277,100 ounces in the Inferred category along all trends and deposits. On behalf of Probe Gold Inc., Dr. David Palmer, President & Chief Executive Officer For further information: Please visit our website at or contact: Seema Sindwani Vice-President of Investor Relations info@ +1.416.777.9467 Forward-Looking Statements Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release. This News Release includes certain 'forward-looking statements' which are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as 'believes', 'anticipates', 'expects', 'estimates', 'may', 'could', 'would', 'will', or 'plan'. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management's expectations. Risks, uncertainties, and other factors involved with forward-looking information could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to, the Company's objectives, goals or future plans, statements, exploration results, potential mineralization, the estimation of mineral resources, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate First Nations and other indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, and those risks set out in the Company's public documents filed on SEDAR. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Yahoo
11-06-2025
- Business
- Yahoo
ONWARD Medical Announces Results of its Annual General Meeting of Shareholders
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Shareholders approve all proposed resolutions EINDHOVEN, The Netherlands, June 11, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury and other movement disabilities, today announces that that all proposed resolutions at its Annual General Meeting of Shareholders (AGM) were duly passed. The meeting was held this afternoon in Amsterdam, the Netherlands at 4:00PM CET. Full details of the resolutions approved during the AGM can be found on the Company's Investor Relations website. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury (SCI) and other movement disabilities. Building on more than a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). The Company's ARC-EX System is cleared for commercial sale in the US. In addition, the Company is developing an investigational implantable system called ARC-IM with and without an implanted brain-computer interface (BCI). Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). To learn more about ONWARD Medical's commitment to partnering with the spinal cord injury community to develop innovative solutions for restoring movement, function, and independence after spinal cord injury, please visit To be kept informed about the Company's technologies, research studies, and the availability of therapies in your area, please complete this webform. For Media Inquiries: Sébastien Cros, VP Communications media@ For Investor Inquiries: investors@ Disclaimer Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Trademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the stylized O-Logo are proprietary and registered trademarks of ONWARD Medical. Unauthorized use is strictly prohibited. ARC-EX Indication for Use (US): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive). Other Investigational Products: All other ONWARD Medical devices and therapies including ARC-IM and ARC-BCI are investigational and not available for commercial use.
Business Wire
11-06-2025
- Business
- Business Wire
3D Investment Partners: Leading Proxy Advisory Firm Glass Lewis Recommends Toho Holdings Shareholders Vote 'AGAINST' the Reappointment of CEO Hiromi Edahiro at the Company's June 2025 AGM
TOKYO--(BUSINESS WIRE)--3D Investment Partners Pte. Ltd., the investment manager of 3D Opportunity Master Fund ('3D' or 'we'), today announced that Glass, Lewis & Co. ('Glass Lewis'), a leading independent provider of proxy research and voting recommendations for the institutional investor community, has recommended that shareholders of Toho Holdings Co., Ltd. ('Toho HD' or the 'Company') (TOKYO: 8129) vote 'AGAINST' the reappointment of Representative Director, President, CEO and CFO Hiromi Edahiro ('Mr. Edahiro') at the Company's 77th Annual General Meeting of Shareholders (the 'AGM'), scheduled to be held on June 27, 2025. In its report, Glass Lewis recognized that 3D 'raises relevant and substantiated concerns regarding Toho Holdings' governance practices' and concluded that shareholders should vote against the reappointment of Mr. Edahiro. In reaching its conclusion, Glass Lewis highlighted Toho HD's fraudulent scheme related to Nihon University Hospital (the 'Nihon University Incident') and found that the incident – which was 'characterized by limited disclosure and unclear accountability' – warranted 'further scrutiny.' Furthermore, Glass Lewis criticized Toho HD's response to the Nihon University Incident particularly; they analyze that this incident suggested 'gaps in the Company's risk awareness and disclosure governance framework.' Glass Lewis noted that: '[T]he Company's involvement in transactions perceived as questionable might have merited a more proactive and transparent response. From the standpoint of risk oversight and shareholder communication, an internal investigation followed by a timely explanation would likely have been more appropriate.' '[T]he Company's first formal disclosure [of the Nihon University Incident] was issued only in response to 3D's public statements ahead of this shareholder meeting. In our view, this reactive approach appears misaligned with generally accepted expectations for corporate transparency. The rationale cited—that disclosure was delayed to protect the Company's reputation—may in fact have had the opposite effect, potentially exacerbating reputational risks.' 3D completely agrees with Glass Lewis that shareholders should expect 'stronger accountability and leadership at the highest levels.' 3D strongly believes that addressing Toho HD's serious governance and compliance failures is essential to enhance the Company's corporate value sustainably, and that substantive change must start at the top of the organization. 3D therefore encourages Toho HD shareholders to vote AGAINST Mr. Edahiro at the Company's upcoming AGM. Note: The passages in quotation marks ("") are direct quotes excerpted by 3D from Glass Lewis' report. The portions in brackets ([ ]) have been added by 3D for additional clarity/context. Permission to use these quotes from Glass Lewis was neither explicitly sought nor obtained. About 3D Investment Partners Pte. Ltd. 3D Investment Partners Pte. Ltd. is an independent Singapore-based Japan focused value investing fund manager founded in 2015. 3D Investment Partners Pte. Ltd. focuses on partnering with management[s] who share its investment philosophy of medium- to long-term value creation through compound capital growth and a common objective of achieving long-term returns. Disclaimer This press release, including annexes is provided for informational purposes only and does not constitute an offer to purchase or sell any security or investment product, nor does it constitute professional or investment advice. This press release should not be relied on by any person for any purpose and is not, and should not be construed as investment, financial, legal, tax or other advice. 3D Investment Partners Pte. Ltd. and its affiliates and related persons ('3DIP') of either believe that the current market price of Toho HD does not reflect its intrinsic value. 3DIP acquired beneficial and/or economic interests based on its own idea that Toho HD securities have been undervalued and provide an attractive investment opportunity and may in the future beneficially own, and/or have an economic interest in, Toho HD securities. 3DIP intends to review its investments in Toho HD on a continuing basis and, depending upon various factors including, without limitation, Toho HD's financial position and strategic direction, the outcome of any discussions with Toho HD, overall market conditions, other investment opportunities available to 3DIP, and the availability of Toho HD securities at prices that would make the purchase or sale of Toho HD securities desirable, 3DIP may, from time to time (in the open market or in private transactions), buy, sell, cover, hedge, or otherwise change the form or substance of any of its investments (including the investment in Toho HD securities) to any degree in any manner permitted by any applicable law, and expressly disclaims any obligation to notify others of any such changes. 3DIP provides no representation or warranty, either expressed or implied, in relation to the accuracy, completeness, or reliability of the information contained herein (including content or quotes from news coverage or other third-party public sources ('Third-Party Materials')), nor is it intended to be a complete statement or summary of the securities, markets, or developments referred to herein. 3DIP expressly disclaims any responsibility or liability for any loss whatsoever arising from any use of, or reliance on, this press release or its contents as a whole or in part by any person, or otherwise whatsoever arising in connection with this press release. 3DIP hereby expressly disclaims any obligation to update or provide additional information regarding the contents of this press release or to correct any inaccuracies in the information contained in this press release. 3DIP disclaims any intention or agreement to be treated as a joint holder (kyodo hoyu sha) under the Financial Instruments and Exchange Act of Japan, a closely related party (missetsu kankei sha) under the Foreign Exchange and Foreign Trade Act with other shareholders, or receiving any power or permission to represent other shareholders in relation to the exercise of their voting rights, and has no intention to solicit, encourage, induce or require any person to cause other shareholders to represent such voting rights. 3DIP does not have the intention to make a proposal, directly or through other shareholders of Toho HD, to transfer or abolish the business or assets of Toho HD and/or Toho HD group companies at the general shareholders meeting of Toho HD. 3DIP does not have the intention or purpose to engage in any conduct which constricts the continuing and stable implementation of business of Toho HD and/or Toho HD group companies. This press release may include Third-Party Materials. Permission to quote from Third-Party Materials in this press release may neither have been sought nor obtained. The content of the Third-Party Materials has not been independently verified by 3DIP and does not necessarily represent the views of 3DIP. The authors and/or publishers of the Third-Party Materials are independent of, and may have different views to 3DIP. Quoting Third-Party Materials in this press release does not imply that 3DIP endorses or concurs with any part of the content of the Third-Party Materials or that any of the authors or publishers of the Third-Party Materials endorses or concurs with any views which have been expressed by 3DIP on the relevant subject matter. The Third-Party Materials may not be representative of all relevant news coverage or views expressed by other third parties on the stated issues. In respect of information that has been prepared by 3DIP (and not otherwise attributed to any other party) and which appears in the English language version of this press release, in the event of any inconsistency between the English language version and the Japanese language version of this press release, the meaning of the Japanese language version shall prevail unless otherwise expressly indicated.
